A recent study published in JAMA Dermatology examined whether oral nicotinamide—also called niacinamide, a form of vitamin B3—may be a cost-effective way to help prevent keratinocyte carcinomas, including basal cell carcinoma and squamous cell carcinoma.
The study analyzed more than 33,000 U.S. veterans with a history of these common skin cancers. Patients taking nicotinamide experienced fewer new skin cancers than those who were not taking it. Among 12,287 nicotinamide users, researchers estimated that 624 skin cancers were prevented annually. The associated reduction in treatment costs more than offset the cost of the supplement.
These findings are encouraging, particularly for patients who have previously developed multiple skin cancers. However, nicotinamide is not appropriate for everyone and should not replace sunscreen, protective clothing, routine skin examinations, or other dermatologist-recommended care. Patients interested in nicotinamide should discuss its potential benefits and appropriate use with their dermatology provider.